AGIOS PHARMACEUTICALS, INC. Investing Cash Flow
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Investing Cash Flow of $181.52 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $40.21M, a 49.08% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $141.31M, a 25.51% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $90.08M.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $95.56M, a 61.90% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2025 was $377.18M, a 3.78% increase from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2024 was $363.44M, a 51.70% increase from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2023 was $239.57M, a 1.52% decline from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2022 was $243.26M, a 80.52% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $40.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $181.52M 10-Q · filed 2026-07-30 | $271.60M derived: sum of 3 quarters · filed 2026-07-30 | $367.15M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $141.31M 10-Q · filed 2026-04-29 | $231.39M derived: sum of 2 quarters · filed 2026-04-29 | $326.94M derived: sum of 3 quarters · filed 2026-04-29 | $405.91M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $90.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $185.63M derived: sum of 2 quarters · filed 2026-02-12 | $264.60M derived: sum of 3 quarters · filed 2026-07-30 | $377.18M 10-K · filed 2026-02-12 |
| 2025-09-30 | $95.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $174.52M derived: sum of 2 quarters · filed 2026-07-30 | $287.11M 10-Q · filed 2025-10-30 | $237.95M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $78.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $191.55M 10-Q · filed 2026-07-30 | $142.40M derived: sum of 3 quarters · filed 2026-07-30 | $393.19M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $112.59M 10-Q · filed 2026-04-29 | $63.43M derived: sum of 2 quarters · filed 2026-04-29 | $314.22M derived: sum of 3 quarters · filed 2026-04-29 | $351.47M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | -$49.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $201.63M derived: sum of 2 quarters · filed 2026-02-12 | $238.88M derived: sum of 3 quarters · filed 2026-02-12 | $363.44M 10-K · filed 2026-02-12 |
| 2024-09-30 | $250.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $288.04M derived: sum of 2 quarters · filed 2025-10-30 | $412.60M 10-Q · filed 2025-10-30 | $508.11M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $37.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $161.81M 10-Q · filed 2025-07-31 | $257.32M derived: sum of 3 quarters · filed 2026-02-12 | $296.66M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $124.56M 10-Q · filed 2025-05-01 | $220.07M derived: sum of 2 quarters · filed 2026-02-12 | $259.42M derived: sum of 3 quarters · filed 2026-02-12 | $306.54M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $95.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $134.85M derived: sum of 2 quarters · filed 2026-02-12 | $181.98M derived: sum of 3 quarters · filed 2026-02-12 | $239.57M 10-K · filed 2026-02-12 |
| 2023-09-30 | $39.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $86.47M derived: sum of 2 quarters · filed 2024-10-31 | $144.06M 10-Q · filed 2024-10-31 | $227.01M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $47.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $104.72M 10-Q · filed 2024-08-01 | $187.67M derived: sum of 3 quarters · filed 2025-02-13 | $291.74M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $57.60M 10-Q · filed 2024-05-02 | $140.55M derived: sum of 2 quarters · filed 2025-02-13 | $244.62M derived: sum of 3 quarters · filed 2025-02-13 | $327.43M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $82.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $187.02M derived: sum of 2 quarters · filed 2025-02-13 | $269.83M derived: sum of 3 quarters · filed 2025-02-13 | $243.26M 10-K · filed 2025-02-13 |
| 2022-09-30 | $104.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $186.88M derived: sum of 2 quarters · filed 2023-11-02 | $160.31M 10-Q · filed 2023-11-02 | $65.89M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $82.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $56.24M 10-Q · filed 2023-08-03 | -$38.18M derived: sum of 3 quarters · filed 2024-02-15 | -$270.91M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$26.57M 10-Q · filed 2023-05-04 | -$120.99M derived: sum of 2 quarters · filed 2024-02-15 | -$353.72M derived: sum of 3 quarters · filed 2024-02-15 | -$651.87M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$94.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$327.15M derived: sum of 2 quarters · filed 2024-02-15 | -$625.30M derived: sum of 3 quarters · filed 2024-02-15 | $1.25B 10-K · filed 2024-02-15 |
| 2021-09-30 | -$232.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$530.88M derived: sum of 2 quarters · filed 2022-11-03 | $1.34B 10-Q · filed 2022-11-03 | $1.41B derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$298.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.58B 10-Q · filed 2022-08-04 | $1.65B derived: sum of 3 quarters · filed 2023-02-23 | $1.52B derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $1.87B 10-Q · filed 2022-05-05 | $1.95B derived: sum of 2 quarters · filed 2023-02-23 | $1.82B derived: sum of 3 quarters · filed 2023-02-23 | $1.84B derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $71.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$54.85M derived: sum of 2 quarters · filed 2023-02-23 | -$32.39M derived: sum of 3 quarters · filed 2023-02-23 | $75.75M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$126.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$103.78M derived: sum of 2 quarters · filed 2021-11-03 | $4.35M 10-Q · filed 2021-11-03 | -$180.42M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $22.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $130.59M 10-Q · filed 2021-07-29 | -$54.18M derived: sum of 3 quarters · filed 2022-02-24 | $26.20M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $108.14M 10-Q · filed 2021-04-29 | -$76.64M derived: sum of 2 quarters · filed 2022-02-24 | $3.74M derived: sum of 3 quarters · filed 2022-02-24 | $68.22M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$184.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$104.39M derived: sum of 2 quarters · filed 2022-02-24 | -$39.91M derived: sum of 3 quarters · filed 2022-02-24 | $91.44M 10-K · filed 2022-02-24 |
| 2019-09-30 | $80.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $144.86M derived: sum of 2 quarters · filed 2020-11-05 | $276.21M 10-Q · filed 2020-11-05 | $263.41M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $64.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $195.83M 10-Q · filed 2020-07-30 | $183.03M derived: sum of 3 quarters · filed 2021-02-25 | $185.80M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $131.35M 10-Q · filed 2020-04-30 | $118.55M derived: sum of 2 quarters · filed 2021-02-25 | $121.32M derived: sum of 3 quarters · filed 2021-02-25 | $25.06M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$12.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$10.03M derived: sum of 2 quarters · filed 2021-02-25 | -$106.29M derived: sum of 3 quarters · filed 2021-02-25 | -$273.82M 10-K · filed 2021-02-25 |
| 2018-09-30 | $2.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$93.49M derived: sum of 2 quarters · filed 2019-10-31 | -$261.02M 10-Q · filed 2019-10-31 | -$219.17M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-06-30 | -$96.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$263.79M 10-Q · filed 2019-08-01 | -$221.94M derived: sum of 3 quarters · filed 2020-02-19 | -$155.53M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-03-31 | -$167.53M 10-Q · filed 2019-05-02 | -$125.68M derived: sum of 2 quarters · filed 2020-02-19 | -$59.27M derived: sum of 3 quarters · filed 2020-02-19 | -$334.99M derived: sum of 4 quarters · filed 2020-02-19 |
| 2017-12-31 | $41.85M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $108.27M derived: sum of 2 quarters · filed 2020-02-19 | -$167.46M derived: sum of 3 quarters · filed 2020-02-19 | -$57.91M 10-K · filed 2020-02-19 |
| 2017-09-30 | $66.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$209.31M derived: sum of 2 quarters · filed 2018-11-01 | -$99.76M 10-Q · filed 2018-11-01 | -$177.27M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-06-30 | -$275.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$166.17M 10-Q · filed 2018-08-02 | -$243.69M derived: sum of 3 quarters · filed 2019-02-14 | -$306.44M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-03-31 | $109.55M 10-Q · filed 2018-05-04 | $32.03M derived: sum of 2 quarters · filed 2019-02-14 | -$30.71M derived: sum of 3 quarters · filed 2019-02-14 | |
| 2016-12-31 | -$77.52M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | -$140.26M derived: sum of 2 quarters · filed 2019-02-14 | -$119.35M 10-K · filed 2019-02-14 | |
| 2016-09-30 | -$62.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$41.83M 10-Q · filed 2017-11-01 | ||
| 2016-06-30 | $20.91M 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | $128.31M 10-K · filed 2018-02-14 | |||
| 2013-12-31 | -$20.41M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-18 | -$101.13M derived: sum of 2 quarters · filed 2014-03-18 | -$87.22M 10-K · filed 2014-03-18 | |
| 2013-09-30 | -$80.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$66.81M 10-Q · filed 2013-11-07 | ||
| 2013-06-30 | $13.91M 10-Q · filed 2013-09-05 | |||
| 2012-12-31 | $19.84M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-18 | $18.11M derived: sum of 2 quarters · filed 2014-03-18 | $23.04M 10-K · filed 2014-03-18 | |
| 2012-09-30 | -$1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $3.21M 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | $4.93M 10-Q · filed 2013-09-05 | |||
| 2011-12-31 | -$22.36M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |